Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naive and virologically suppressed HIV-1 infected patients

被引：0

作者：

Antinori, Andrea ^{[1
]}

Santoro, Maria Mercedes ^{[2
]}

Gagliardini, Roberta ^{[1
]}

Marchetti, Giulia ^{[3
]}

Mondi, Annalisa ^{[1
]}

Cento, Valeria ^{[4
]}

Perno, Carlo Federico ^{[5
,22
]}

Andreoni, Massimo ^{[6
]}

Ceccherini-Silberstein, Francesca ^{[2
]}

Cossarizza, Andrea ^{[7
]}

Clerici, Mario ^{[8
,9
]}

Monforte, Antonella D'Arminio ^{[10
]}

De Luca, Andrea ^{[11
]}

Di Biagio, Antonio ^{[12
]}

Di Perri, Giovanni ^{[13
]}

Galli, Massimo ^{[14
]}

Girardi, E. ^{[1
]}

Gori, Andrea ^{[15
]}

Lazzarin, Adriano ^{[16
]}

Lichtner, Miriam ^{[17
]}

Lo Caputo, Sergio ^{[18
]}

Madeddu, Giordano ^{[19
]}

Maggiolo, Franco ^{[20
]}

Mussini, Cristina ^{[21
]}

Re, Maria Carla ^{[23
]}

Ripamonti, Diego ^{[24
]}

Rizzardini, Giuliano ^{[25
]}

Zazzi, Maurizio ^{[26
]}

机构：

[1] IRCCS, Natl Inst Infect Dis L Spallanzani, Rome, Italy

[2] Univ Roma Tor Vergata, Dept Expt Med, Rome, Italy

[3] Univ Milan, Clin Infect Dis, Dept Hlth Sci, ASST Santi Paolo & Carlo,Presidio San Paolo, Milan, Italy

[4] Univ Milan, Residency Microbiol & Virol, Milan, Italy

[5] Univ Milan, Dept Oncol & Oncohematol, Milan, Italy

[6] Univ Roma Tor Vergata, Infect Dis, Rome, Italy

[7] Univ Modena & Reggio Emilia, Dept Med & Surg Sci Children & Adults, Modena, Italy

[8] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy

[9] IRCCS Don Carlo Gnocchi Fdn, Milan, Italy

[10] Univ Milan, Inst Infect Dis, Dept Hlth Sci, ASST Santi Paolo & Carlo, Milan, Italy

[11] Siena Univ Hosp, Infect Dis Unit, Siena, Italy

[12] Policlin Hosp San Martino, Infect Dis Clin, Genoa, Italy

[13] Univ Turin, Dept Med Sci, Unit Infect Dis, Turin, Italy

[14] Univ Milan, Infect Dis Unit, DIBIC Luigi Sacco, Milan, Italy

[15] Univ Milan, Fdn IRCCS Ca Granda, Infect Dis Unit, Osped Maggiore Policlin, Milan, Italy

[16] IRCCS San Raffaele Sci Inst, Clin Infect Dis, Milan, Italy

[17] Sapienza Univ, Dept Publ Hlth & Infect Dis, Rome, Italy

[18] Univ Bari Aldo Moro, Clin Infect Dis, Bari, Italy

[19] Univ Sassari, Dept Clin & Expt Med, Sassari, Italy

[20] AO Giovanni XXIII, Div Infect Dis, Bergamo, Italy

[21] Azienda Osped Univ Policlin Modena, Infect Dis Clin, Modena, Italy

[22] Univ Milan, Oncol & Oncolzematol, Milan, Italy

[23] Univ Bologna, Sch Med, Microbiol Sect, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[24] ASST Papa Giovanni XXIII, Infect Dis Unit, Bergamo, Italy

[25] ASST Fatebenefratelli Sacco, Div Infect Dis, Milan, Italy

[26] Univ Siena, Dept Med Biotechnol, Siena, Italy

来源：

NEW MICROBIOLOGICA | 2019年 / 42卷 / 02期

关键词：

HIV; Two-drug regimens; Dolutegravir; Antireuoviral therapy; HIV drug-resistance; Virological efficacy; ATAZANAVIR/RITONAVIR PLUS LAMIVUDINE; HIV-INFECTED PATIENTS; REVERSE-TRANSCRIPTASE INHIBITOR; RITONAVIR-BOOSTED ATAZANAVIR; NON-INFERIORITY; OPEN-LABEL; TRIPLE THERAPY; DUAL THERAPY; TENOFOVIR-EMTRICITABINE; BUDGET IMPACT;

D O I：

暂无

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

New strategies for HIV treatment able to reduce drug-exposure, medium-long term toxicities and costs are a recognized clinical need. The availability of newer drugs with improved potency and tolerability, as well as high genetic barrier to resistance, makes antiretroviral-sparing strategies with two-drug regimens (2DRs) particularly attractive. Substantial evidence has been generated over the last few years supporting 2DR in virologically suppressed HIV infected patients for whom a therapy switch is planned. More recently, very promising data on 2DR in naive patients have also been reported. The main purpose of this consensus is to provide an overview of guideline indications and recommendations, and the most recent data from clinical studies of 2DR in both naive and virologically suppressed patients. As an expert consensus, suggestions and indications on the use and management of 2DR are also provided.

引用

页码：69 / 80

页数：12

共 102 条

[91] The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression [J].

Serrano-Villar, Sergio ;

Gutierrez, Carolina ;

Vallejo, Alejandro ;

Hernandez-Novoa, Beatriz ;

Diaz, Laura ;

Abad Fernandez, Maria ;

Madrid, Nadia ;

Dronda, Fernando ;

Zamora, Javier ;

Angeles Munoz-Fernandez, Maria ;

Moreno, Santiago .

JOURNAL OF INFECTION, 2013, 66 (01) :57-66

[92]

SIMIT, 2017, LIN GUID IT SULL FAR

[93] A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study [J].

Spagnuolo, Vincenzo ;

Galli, Laura ;

Poli, Andrea ;

Bigoloni, Alba ;

Fumagalli, Luca ;

Gianotti, Nicola ;

Nozza, Silvia ;

Ferrari, Davide ;

Locatelli, Massimo ;

Lazzarin, Adriano ;

Castagna, Antonella .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 :477-479

[94] Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment [J].

Stellbrink, Hans-Juergen ;

Le Fevre, Eric ;

Carr, Andrew ;

Saag, Michael S. ;

Mukwaya, Geoffrey ;

Nozza, Silvia ;

Valluri, Srinivas Rao ;

Vourvahis, Manoli ;

Rinehart, Alex R. ;

McFadyen, Lynn ;

Fichtenbaum, Carl ;

Clark, Andrew ;

Craig, Charles ;

Fang, Annie F. ;

Heera, Jayvant .

AIDS, 2016, 30 (08) :1229-1238

[95] Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial [J].

Taiwo, Babafemi O. ;

Marconi, Vincent C. ;

Berzins, Baiba ;

Moser, Carlee B. ;

Nyaku, Amesika N. ;

Fichtenbaum, Carl J. ;

Benson, Constance A. ;

Wilkin, Timothy ;

Koletar, Susan L. ;

Colasanti, Jonathan ;

Acosta, Edward P. ;

Li, Jonathan Z. ;

Sax, Paul E. .

CLINICAL INFECTIOUS DISEASES, 2018, 66 (11) :1794-1797

[96] ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA < 500 000 Copies/mL [J].

Taiwo, Babafemi O. ;

Zheng, Lu ;

Stefanescu, Andrei ;

Nyaku, Amesika ;

Bezins, Baiba ;

Wallis, Carole L. ;

Godfrey, Catherine ;

Sax, Paul E. ;

Acosta, Edward ;

Haas, David ;

Smith, Kimberly Y. ;

Sha, Beverly ;

Van Dam, Cornelius ;

Gulic, Roy M. .

CLINICAL INFECTIOUS DISEASES, 2018, 66 (11) :1689-1697

[97]

Underwood M., 2018, J INT AIDS SOC

[98] Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study [J].

van Lunzen, Jan ;

Pozniak, Anton ;

Gatell, Jose M. ;

Antinori, Andrea ;

Klauck, Isabelle ;

Serrano, Oscar ;

Baakili, Adyb ;

Osiyemi, Olayemi ;

Sevinsky, Heather ;

Girard, Pierre-Marie .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 71 (05) :538-543

[99] Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro [J].

Weiss, Johanna ;

Haefeli, Walter Emil .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 41 (05) :484-487

[100]

Wijting I., 2018, HIV MED

← 2 3 4 5 6 7 8 9 10 11 →